SCHEMBL26495342

SCHEMBL26495342

CNCCCCCCN(C)CCO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR2 O95136 1/20 0.41
S1PR1 P21453 1/20 0.41
S1PR3 Q99500 1/20 0.41
S1PR5 Q9H228 1/20 0.41
EPHX1 P07099 1/20 0.41
CHRM2 P08172 2/20 0.39
PRMT3 O60678 1/20 0.37
CARM1 Q86X55 1/20 0.37
PRMT6 Q96LA8 1/20 0.37
PRMT1 Q99873 1/20 0.37
PRMT8 Q9NR22 1/20 0.37
KDM4C Q9H3R0 6/20 0.37
KDM4A O75164 3/20 0.37
MAPT P10636 1/20 0.35
PAOX Q6QHF9 1/20 0.32
KDM5A P29375 3/20 0.32
PHF8 Q9UPP1 2/20 0.32
SIGMAR1 Q99720 3/20 0.31
ALDH1A1 P00352 1/20 0.31
TSHR P16473 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26494037 1.00 S1PR2 (0.41) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL26495264 0.98 PRMT3 (0.39) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL3317561 0.93 PRMT3 (0.42) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL26494041 0.91 S1PR2 (0.41) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL26494039 0.91 S1PR2 (0.41) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL26495343 0.91 S1PR2 (0.41) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL26495349 0.91 S1PR2 (0.41) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL14178222 0.91 EPHX1 (0.48) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL25075486 0.89 PRMT3 (0.39) S1PR2S1PR1S1PR3S1PR5EPHX1
SCHEMBL26495268 0.89 PRMT3 (0.39) S1PR2S1PR1S1PR3S1PR5EPHX1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230320995-A1 IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES CAPSTAN THERAPEUTICS, INC. (US) 2023-10-12 US disclosed
WO-2023196444-A1 IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES CAPSTAN THERAPEUTICS, INC. (US) 2023-10-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230320995-A1 IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES PLTP, LNPEP, PLIN3 S1PR2 927/4885S1PR1 743/4885S1PR3 549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.